Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke
AssigneeTrustees of Boston University
InventorsNelson Ruiz-Opazo, Victoria L. M. Herrera, Francis Joseph Carr
Life of this patent
Estimating the term…
Abstract
Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.
Claims9
A method of inhibiting angiogenesis in a subject having a disease or disorder dependent or modulated by angiogenesis, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
- (i) a pharmaceutically acceptable carrier and (ii) an isolated anti-DEspR antibody or antigen-binding fragment thereof that specifically binds DEspR (dual endothelin/VEGF signal peptide receptor) of SEQ ID NO:
- 3 and that has an EC50 for binding to DEspR of SEQ ID NO:
- 3 of 12 μg/ml or less and comprising heavy and light chain sequences comprising complementarity determining regions (CDRs) of a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 14;
- a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 15;
- a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 16;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 28;
- a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 29;
- and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 30.
A method of inhibiting angiogenesis in a subject having a disease or disorder dependent or modulated by angiogenesis, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
- (i) a pharmaceutically acceptable carrier, and (ii) an isolated antibody or antigen-binding fragment thereof capable of binding to DEspR (dual endothelin-1/VEGF signal peptide receptor) of SEQ ID NO:
- 3 and comprising heavy and light chain sequences comprising complementarity determining regions (CDRs) of a heavy chain CDR1 having the amino acid sequence of SEQ ID NO:
- 14;
- a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:
- 15;
- a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:
- 16;
- a light chain CDR1 having the amino acid sequence of SEQ ID NO:
- 28;
- a light chain CDR2 having the amino acid sequence of SEQ ID NO:
- 29;
- and a light chain CDR3 having the amino acid sequence of SEQ ID NO:
- 30.
Dependencies are inferred from the claim text.